Skip to content

Clinical study of Yishen Qufeng prescription for improving proteinuria in diabetic nephropathy

Clinical and mechanism study of Yishen Qufeng prescription for inhibiting podocyte scorch death and improving diabetic nephropathy

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300078032
Enrollment
Unknown
Registered
2023-11-27
Start date
2023-12-01
Completion date
Unknown
Last updated
2023-12-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic nephropathy

Interventions

Treatment group:Basic treatment (Including control of dietary nutrition, control of blood pressure, control of blood sugar, correct blood lipid disorders, improve anemia, Tripterygium Glycosides) + Yi
Control group:Basic treatment

Sponsors

Jiangsu Province Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Non dialysis patients who meet the diagnostic criteria of diabetes nephropathy and whose clinical stages are G3A2~G4A3, and whose TCM syndrome differentiation belongs to the syndrome of spleen and kidney qi deficiency and wind evil damaging the kidney; 2, age 18-80 years old, male and female; 3, informed consent, volunteer test, and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes, difficult blood sugar control, acute complications such as diabetic ketoacidosis; 2, complicated with serious heart, brain, liver, blood system diseases; 3. Proteinuria caused by other primary diseases; 4. Combined with other kidney diseases; 5. Diabetic nephropathy patients who continue to receive dialysis or kidney transplantation; 6. Pregnant and lactating women; 7, can not cooperate or can not follow the interviewer on time. 8. I am participating in another clinical study.

Design outcomes

Primary

MeasureTime frame
UTP;Urine ACR;Serum creatinine;eGFR;

Secondary

MeasureTime frame
hemoglobin;FBG;HbA1c;Blood urea nitrogen;Blood lipid;serum UA;Cysc;Urine red blood cell count;Urine white blood cell count;IL-1ß;IL-18;IL-6;Blood pressure;eyesight;

Countries

China

Contacts

Public ContactChen Yong

Jiangsu Province Hospital of Chinese Medicine

yckirsch@163.com+86 177 2151 5982

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026